IPO
Recipharm announced the intention to end operations in Ashton-under-Lyne, United Kingdom
Promore Pharma AB (publ) publishes its Year-end report for 2018 at 09.00 CET on 26 February 2019
Strong Launch Continues With More than 550 Patients on Reimbursed Commercial Crysvita® (burosumab) Therapy in the United States at End of 4th Quarter 2018, 80 Percent Increase Versus End of 3rd Quarter
ASIT biotech, a Belgian biopharmaceutical company specialized in the research and development of innovative allergy immunotherapy products, announces its preliminary financial calendar for 2019.
Medtronic plc announced financial results for its third quarter of fiscal year 2019, which ended January 25, 2019.
NOXXON Pharma N.V., a biotechnology company focused on improving cancer treatments by targeting the tumor microenvironment, published a shareholder letter addressing recent clinical data and outlining its corporate strategy going forward.
Immunicum announced a collaboration with Merck KGaA, Darmstadt, Germany, and Pfizer to evaluate ilixadencel in combination with Avelumab in multi-indication phase Ib/II study ILIAD.
Karolinska Development AB publishes its Q4 and 2018 Year-End Report with a positive quarterly and full-year result. The full report is available on the Company’s website.
Microbix Biosystems Inc. reports results for its first quarter of fiscal 2019, the three-month period ending December 31, 2018 (“Q1"), with lower sales, improving percentage gross margin, improving and positive cash flow from operations and progress toward its operational goals.
Retrophin, Inc. announced it will report fourth quarter and full year 2018 financial results on Tuesday, February 26, 2019 after the close of the U.S. financial markets.
PRESS RELEASES